Gupta R, Kumar A, Malaviya A N
Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.
Rheumatol Int. 1997;17(3):101-3. doi: 10.1007/s002960050016.
Over the last 10 years, 17 patients (13 males and 4 females) diagnosed as having classical polyarteritis nodosa (PAN) were treated and followed up in the rheumatology clinic of our institute. The median age and duration of symptoms at presentation were 29 years (range 13-59) and 9.5 months, respectively. Patients presented with the typical clinical picture of classical PAN. The diagnosis was established with the help of an aortogram (7/10), sural nerve biopsy (7/8), muscle biopsy (5/7) and renal biopsy (3/4). For reasons not known, none of the 17 patients was HBsAg positive. Patients were treated with a combination of oral prednisolone (1 mg/kg per day) for 6 weeks, which was slowly tapered off over 6 months, and monthly intravenous cyclophosphamide pulses (15 mg/kg) for the first 6 months, followed by 3-monthly pulses for a total of 2 years. Remission was achieved in 14 patients after a median of 5 months of treatment. Remission was stable for a median of 5 years of follow-up. Three patients did not respond well and died within 6 months of diagnosis. The causes of death in these were intracerebral haemorrhage in one patient and gastrointestinal bleeding in two patients. This experience is in accord with the reported literature that classical PAN is mostly a monophasic disease with either an excellent response to the appropriate immunosuppressive therapy and a long remission or a downhill course culminating in death. A chronic course is rare.
在过去10年里,我院风湿病门诊对17例诊断为经典型结节性多动脉炎(PAN)的患者进行了治疗和随访。这些患者中男性13例,女性4例。就诊时的中位年龄和症状持续时间分别为29岁(范围13 - 59岁)和9.5个月。患者呈现出经典型PAN的典型临床表现。通过主动脉造影(10例中的7例)、腓肠神经活检(8例中的7例)、肌肉活检(7例中的5例)和肾活检(4例中的3例)确诊。不知为何,17例患者中无一例HBsAg阳性。患者接受口服泼尼松龙(每日1 mg/kg)联合治疗6周,之后在6个月内缓慢减量,最初6个月每月静脉注射环磷酰胺冲击治疗(15 mg/kg),之后每3个月冲击治疗一次,共持续2年。治疗中位时间5个月后,14例患者病情缓解。缓解状态在中位5年的随访期内保持稳定。3例患者反应不佳,在诊断后6个月内死亡。其中1例死于脑出血,2例死于胃肠道出血。这一经验与已发表的文献一致,即经典型PAN大多为单相疾病,对适当的免疫抑制治疗反应良好,缓解期长,否则病情逐渐恶化直至死亡。慢性病程较为罕见。